CD47 and diffuse large B-cell lymphoma: Understanding factors in the TME that mediate DLBCL relapse following R-CHOP is also important in terms of incorporating current immunotherapeutics such as bispecific CD20-CD3 T-cell engagers, CD19 CAR-T cells and anti-CD47 antibodies into front-line treatment regimens for DLBCL.